Results 121 to 130 of about 24,911 (203)

Molecular devolution in chronic myelomonocytic leukemia during treatment with decitabine/cedazuridine: A case report. [PDF]

Ann Hematol
Geissler K, Mitterbauer-Hohendanner G, Jäger R.   +2 more
europepmc   +1 more source

Epigenetic synergy between decitabine and platinum derivatives [PDF]

, 2015

core   +1 more source

Individualized decitabine dosing for post-HSCT maintenance in MDS and secondary AML from MDS: long-term outcomes from the PODAC trial and matched controls. [PDF]

Ther Adv Hematol
Park S, Choi S, Han S, Kim YJ.
europepmc   +1 more source

Successful Treatment of Primary Poor Graft Function After Haploidentical Hematopoietic Stem Cell Transplantation With Low-Dose Decitabine Followed by Donor Lymphocyte Infusion and Eltrombopag. [PDF]

Cancer Med
Yuan J, Cao J, Ye P, Wang T, Chen D, Li S, Pei R, Zhang J, Lu Y.   +8 more
europepmc   +1 more source

Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials [PDF]

, 2016

core   +1 more source

Real-world study of use patterns and clinical outcomes for patients with myelodysplastic syndrome initiating oral decitabine and cedazuridine or intravenous/subcutaneous hypomethylating agents. [PDF]

Ther Adv Hematol
Zeidan AM, Zhao R, Tepsick JG, Lan Z, Salimi T.   +4 more
europepmc   +1 more source

REST-driven upregulation of SFXN3 promotes AML progression via Wnt/β-catenin activation and confers decitabine resistance. [PDF]

Transl Oncol
Wang X, Huang Y, Sun M, Cai S, Hu X, Zheng Y, Fang S, Li S, Tu Y, Tang H.   +9 more
europepmc   +1 more source

The effects of adding decitabine to conditioning regimen for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. [PDF]

Ann Hematol
Luo C, Zhang J, Huang X, Wu G, Huang Y, Ding Y, Huang Z, Song Q, Chen J, Li X, Xu S.   +10 more
europepmc   +1 more source

Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia [PDF]

, 2013

core   +1 more source

A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer. [PDF]

Cancer
Miller KD, Thomas A, Althouse S, Zang Y, Conder E, Burgos R, Schneider BP, Ballinger T, Douglas E, Ansley K, Jang HJ, Chung W, Issa JP, Nephew KP, Rassool FV.   +14 more
europepmc   +1 more source